Olin Corporation reports Q2 results today against a backdrop of heavy but easing short interest, a wall of analyst downgrades, and a stock that has lost 6% in the past week alone.
Short sellers remain firmly entrenched, but they are pulling back ahead of the print. Short interest has dropped 9% over the past week to 12.4% of the free float — still elevated by any measure, and the ORTEX short score of 55.7 keeps the name in bearish territory. That said, the borrow market is nowhere near distressed: availability is running at over 900% of short interest, meaning lenders have roughly nine shares available for every one currently borrowed, and the cost to borrow is just 0.44%. There is no squeeze pressure visible in the lending data. The one-week decline in shorts — from roughly 15.6 million shares to 14.1 million — may reflect positioning ahead of today's release rather than any fundamental change of heart.
The analyst community has moved decisively in one direction: lower. Goldman Sachs cut its target from $31 to $24 in mid-July, and Truist followed the same week, trimming to $24. BofA made the most aggressive move in late June, downgrading outright from Buy to Underperform and slashing its target from $32 to $21 — the only sell-rated view in the group. The mean target now sits at $26.14, implying roughly 18% upside to the current price of $22.17, but every recent move has been a reduction. Bears point to double-digit sales declines in Olin's CAPV business, elevated maintenance costs, and the risk that caustic soda markets deteriorate faster than expected. Bulls counter that 2026 represents the earnings trough and that management's cost restructuring — combined with improving momentum in the Winchester ammunition segment — sets up a recovery, with 30-day EPS momentum turning positive again after a weak June.
The peer group confirms the sector-wide pressure. TROX, HUN, CE, and KRO are all down 8–13% on the week. DOW and HUN managed to bounce on the day, but the macro read for commodity chemicals is broadly negative. Hotchkis and Wiley, Olin's largest institutional shareholder with 13.2% of shares, added 194,000 shares as of late May — a signal that at least one patient, value-oriented holder is not yet alarmed. Insider activity has been minimal, with only small award-related sells at the divisional level over the past few months, and the CEO's last transaction was a stock award in March.
Today's print is less about whether Olin can show a path to recovery and more about whether the pace of that recovery — specifically any guidance on CAPV pricing and maintenance cost normalisation — is fast enough to justify holding at current levels against a consensus that has spent the past two months moving in one direction.
See the live data behind this article on ORTEX.
Open OLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
